EP2755687A4 - Anticorps reconnaissant un épitope conçu arbitrairement d'au moins trois résidus d'acides aminés dans un peptide, et procédé de génération de celui-ci - Google Patents

Anticorps reconnaissant un épitope conçu arbitrairement d'au moins trois résidus d'acides aminés dans un peptide, et procédé de génération de celui-ci

Info

Publication number
EP2755687A4
EP2755687A4 EP12832007.4A EP12832007A EP2755687A4 EP 2755687 A4 EP2755687 A4 EP 2755687A4 EP 12832007 A EP12832007 A EP 12832007A EP 2755687 A4 EP2755687 A4 EP 2755687A4
Authority
EP
European Patent Office
Prior art keywords
peptide
generating
amino acid
acid residues
antibody recognizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12832007.4A
Other languages
German (de)
English (en)
Other versions
EP2755687A2 (fr
Inventor
Zhiwei Wu
Xilin Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Y-Clone Medical Sciences Co Ltd
Original Assignee
SUZHOU NAAO NEW MATERIAL SCIENCES Co Ltd
SUZHOU NAAO NEW MATERIAL SCIENCES CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SUZHOU NAAO NEW MATERIAL SCIENCES Co Ltd, SUZHOU NAAO NEW MATERIAL SCIENCES CO Ltd filed Critical SUZHOU NAAO NEW MATERIAL SCIENCES Co Ltd
Publication of EP2755687A2 publication Critical patent/EP2755687A2/fr
Publication of EP2755687A4 publication Critical patent/EP2755687A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP12832007.4A 2011-09-17 2012-09-17 Anticorps reconnaissant un épitope conçu arbitrairement d'au moins trois résidus d'acides aminés dans un peptide, et procédé de génération de celui-ci Withdrawn EP2755687A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535988P 2011-09-17 2011-09-17
PCT/US2012/055771 WO2013040564A2 (fr) 2011-09-17 2012-09-17 Anticorps reconnaissant un épitope conçu arbitrairement d'au moins trois résidus d'acides aminés dans un peptide, et procédé de génération de celui-ci

Publications (2)

Publication Number Publication Date
EP2755687A2 EP2755687A2 (fr) 2014-07-23
EP2755687A4 true EP2755687A4 (fr) 2015-04-08

Family

ID=47884023

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12832007.4A Withdrawn EP2755687A4 (fr) 2011-09-17 2012-09-17 Anticorps reconnaissant un épitope conçu arbitrairement d'au moins trois résidus d'acides aminés dans un peptide, et procédé de génération de celui-ci

Country Status (7)

Country Link
EP (1) EP2755687A4 (fr)
JP (2) JP2014527085A (fr)
CN (1) CN104039350B (fr)
AU (2) AU2012308212A1 (fr)
CA (1) CA2855781A1 (fr)
HK (1) HK1200359A1 (fr)
WO (1) WO2013040564A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245313B2 (en) 2014-10-24 2019-04-02 Versitech Limited DNA motif compounds and methods for inducing specific antibodies and cellular immunity
CN111153996B (zh) * 2020-01-10 2021-12-14 苏州睿瀛生物技术有限公司 G蛋白偶联受体的抗体及其制备方法和g蛋白偶联受体试剂盒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09504296A (ja) * 1993-10-26 1997-04-28 シンテロ インコーポレイテッド Ｈｉｖ粘膜感染の阻止
EP0725838A4 (fr) * 1993-10-26 1997-02-26 United Biomedical Inc Bibliotheques structurees d'antigenes de synthese utilisables a des fins de diagnostic, de vaccin et de therapie
US6441140B1 (en) * 1998-09-04 2002-08-27 Cell Signaling Technology, Inc. Production of motif-specific and context-independent antibodies using peptide libraries as antigens
US9289487B2 (en) * 1999-09-14 2016-03-22 Antigen Express, Inc. II-key/antigenic epitope hybrid peptide vaccines
FR2809402A1 (fr) * 2000-05-26 2001-11-30 Dev Des Antigenes Combinatoire Bibliotheques peptidiques combinatoires convergentes et leur application a la vaccination contre le virus de l'hepatite c
AU2005211424A1 (en) * 2004-02-02 2005-08-18 Mixture Sciences, Inc. Peptide mixtures with immunomodulatory activity
AU2008309940B2 (en) * 2007-10-09 2013-11-14 Technologie Integrale Ltd. HIV preventive vaccine based on HIV specific antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CLAUDIA CHARLES-NIÑO ET AL: "Variable epitope libraries: New vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response", VACCINE, vol. 29, no. 32, 1 July 2011 (2011-07-01), pages 5313 - 5321, XP055172207, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2011.05.007 *
JAVAHERIAN K ET AL: "PRINCIPAL NEUTRALIZING DOMAIN OF THE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ENVELOPE PROTEIN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 86, no. 17, 1 September 1989 (1989-09-01), pages 6768 - 6772, XP000068860, ISSN: 0027-8424, DOI: 10.1073/PNAS.86.17.6768 *
PEDROZA-ROLDAN C ET AL: "Variable epitope library-based vaccines: Shooting moving targets", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 47, no. 2-3, 1 December 2009 (2009-12-01), pages 270 - 282, XP026886945, ISSN: 0161-5890, [retrieved on 20091023], DOI: 10.1016/J.MOLIMM.2009.09.024 *
See also references of WO2013040564A2 *

Also Published As

Publication number Publication date
AU2012308212A1 (en) 2014-03-27
AU2017251715A1 (en) 2017-11-09
CA2855781A1 (fr) 2013-03-21
WO2013040564A2 (fr) 2013-03-21
HK1200359A1 (en) 2015-08-07
JP2017141291A (ja) 2017-08-17
EP2755687A2 (fr) 2014-07-23
CN104039350B (zh) 2019-07-05
JP2014527085A (ja) 2014-10-09
WO2013040564A3 (fr) 2013-06-27
CN104039350A (zh) 2014-09-10

Similar Documents

Publication Publication Date Title
HK1249406A1 (zh) 芳族陽離子肽和使用它們的方法
HK1247627A1 (zh) 多特異性fab融合蛋白及其使用方法
ZA201308251B (en) Amino acid sequence presenting fusion polypeptide and its use
HK1223550A1 (zh) 芳香族陽離子肽及其用途
HK1199892A1 (en) Modified mini-hepcidin peptides and methods of using thereof
IL230918A0 (en) Modified proteins and peptides
HK1244540A1 (zh) 芳香族陽離子肽及其用途
GB2509565B (en) Photo-dissociation of proteins and peptides in a mass spectrometer
HK1197028A1 (en) Aromatic-cationic peptides and uses of same
IL229353B (en) Dolestatin derivatives related to unnatural amino acids and medicinal preparations that include them
EP2734938A4 (fr) Procédé et système de classement dans une interface-utilisateur en langage naturel
HK1201443A1 (en) Aromatic-cationic peptides and uses of same
PT2768848T (pt) Agentes e métodos para a expressão e secreção de péptidos e proteínas
IL229360A0 (en) Peptide extraction process and its use in liquid phase peptide synthesis
SI2839003T1 (sl) Zmanjšanje tvorbe amidiranih aminokislin v celičnih linijah za izražanje proteinov
HK1200359A1 (en) Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
EP2695892A4 (fr) Peptide pouvant induire un anticorps capable de reconnaître la stéréostructure du vih
IL234753B (en) A method for preparing a recombinant peptide and the prepared peptide
EP2680879A4 (fr) Lieurs peptidiques pour compositions de polypeptide et procédés pour les utiliser
EP2771689A4 (fr) Peptides usp2a et anticorps
EP2577537A4 (fr) Méthode de préparation d'inhibiteurs peptidiques d'une enzyme activée par des lipides et peptides produits par cette méthode
GB201121233D0 (en) Modified proteins and peptides
GB201121226D0 (en) Modified proteins and peptides
GB201121236D0 (en) Proteins and peptides

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140410

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SUZHOU NAAO NEW MATERIAL SCIENCES CO., LTD.

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20150309

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/18 20060101ALI20150303BHEP

Ipc: A61K 38/17 20060101ALI20150303BHEP

Ipc: A61K 39/395 20060101AFI20150303BHEP

Ipc: C07K 16/10 20060101ALI20150303BHEP

Ipc: A61K 38/16 20060101ALI20150303BHEP

17Q First examination report despatched

Effective date: 20160613

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: Y-CLONE MEDICAL SCIENCES CO., LTD.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210921